全球第二大啤酒制造商海因克尔向英国酒吧和餐饮业发出警告，称GLP-1减肥药物（包括Ozempic和Wegovy等）使用的激增可能导致啤酒和苹果酒销售下滑1。根据美国摩根大通的研究，去年有1000万人在美国使用减肥药物1。海因克尔在演示文稿中指出，GLP-1使用者往往会减少饮酒次数、降低酒水销售量，并倾向于选择低酒精产品1。
面对这一趋势，海因克尔建议酒吧采取应对措施，推广半品脱装、低度和零度酒精选项，同时配套小食盘服务1。数据显示，英国酒吧、酒馆和餐厅在截至2月的一年内啤酒销售额近140亿英镑，其中低度和无酒精产品的销售额不足3亿英镑1。Circana、NIQ和KAM等研究公司的调查证实了GLP-1使用者饮酒量下降的趋势1。不过，业界对该药物影响的程度看法不一，Carlsberg表示现有数据不支持GLP-1药物对啤酒消费产生显著影响的观点1。
Heineken, the world's second-largest beer manufacturer, has cautioned British pubs and hospitality venues that the surging use of GLP-1 weight-loss medications such as Ozempic and Wegovy could significantly reduce beer and cider sales 1. The brewer highlighted in a presentation that users of these drugs tend to drink less frequently, consume smaller quantities of alcohol, and gravitate toward lower-alcohol products 1.
Research supports Heineken's concerns about the market impact. According to a J.P. Morgan study, approximately 10 million Americans used weight-loss drugs in the previous year 1. Multiple research firms—including Circana, NIQ, and KAM—have documented declining alcohol consumption among GLP-1 users 1. In the UK, beer sales in pubs, bars, and restaurants reached approximately 14 billion pounds over the year ending in February, yet low and zero-alcohol products accounted for less than 300 million pounds of that total 1.
In response to this trend, Heineken has recommended that venues promote half-pint servings, low-alcohol options, and alcohol-free beverages, alongside small food plates to complement these offerings 1. However, opinion within the beverage industry remains divided. Carlsberg has contested the premise, stating that available data does not substantiate the claim that GLP-1 medications are affecting beer consumption 1.
评论
还没有评论，欢迎留下第一条。